British American Tobacco p.l.c.

BUL:BMT Stock Report

Market Cap: €76.5b

British American Tobacco Valuation

Is BMT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BMT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BMT (€34.93) is trading below our estimate of fair value (€75.15)

Significantly Below Fair Value: BMT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BMT?

Key metric: As BMT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BMT. This is calculated by dividing BMT's market cap by their current revenue.
What is BMT's PS Ratio?
PS Ratio2.4x
SalesUK£26.18b
Market CapUK£63.49b

Price to Sales Ratio vs Peers

How does BMT's PS Ratio compare to its peers?

The above table shows the PS ratio for BMT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.9x
MO Altria Group
4.5x1.0%US$91.2b
ITC ITC
7.7x7.0%₹5.8t
2914 Japan Tobacco
2.4x4.6%JP¥7.4t
PM Philip Morris International
5.2x6.5%US$193.1b
BMT British American Tobacco
2.4x1.9%€63.5b

Price-To-Sales vs Peers: BMT is good value based on its Price-To-Sales Ratio (2.4x) compared to the peer average (4.9x).

Price to Sales Ratio vs Industry

How does BMT's PS Ratio compare vs other companies in the Global Tobacco Industry?

11 CompaniesPrice / SalesEstimated GrowthMarket Cap
BMT 2.4xIndustry Avg. 2.1xNo. of Companies11PS01.63.24.86.48+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BMT is expensive based on its Price-To-Sales Ratio (2.4x) compared to the Global Tobacco industry average (2.1x).

Price to Sales Ratio vs Fair Ratio

What is BMT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BMT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BMT's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BMT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€34.93
€39.28
+12.4%
16.0%€53.26€32.68n/a10
Dec ’25n/a
€38.23
0%
17.5%€52.99€30.11n/a10
Nov ’25€31.95
€37.57
+17.6%
18.7%€52.83€30.02n/a10
Oct ’25€33.99
€38.13
+12.2%
17.4%€52.71€30.55n/a10
Sep ’25n/a
€36.75
0%
17.2%€51.24€29.11n/a12
Aug ’25n/a
€36.87
0%
17.9%€52.23€29.68n/a12
Jul ’25€29.82
€36.11
+21.1%
18.9%€51.81€28.26n/a12
Jun ’25n/a
€36.16
0%
18.7%€51.75€28.23n/a12
May ’25€27.63
€36.15
+30.8%
19.9%€51.10€27.87n/a12
Apr ’25n/a
€36.35
0%
19.9%€51.52€28.10n/a12
Mar ’25n/a
€36.36
0%
19.2%€51.42€28.05n/a13
Feb ’25n/a
€36.53
0%
18.9%€51.49€28.08n/a13
Jan ’25n/a
€36.79
0%
17.8%€49.91€26.70n/a15
Dec ’24n/a
€40.97
0%
15.4%€54.92€32.14n/a15
Nov ’24€28.22
€40.69
+44.2%
15.0%€54.35€31.80€31.9515
Oct ’24n/a
€40.71
0%
14.9%€54.46€31.87€33.9915
Sep ’24€30.55
€41.51
+35.9%
14.6%€55.17€32.28n/a16
Aug ’24n/a
€41.44
0%
14.4%€54.78€32.05n/a16
Jul ’24n/a
€41.79
0%
13.8%€54.66€31.98€29.8216
Jun ’24€29.87
€43.61
+46.0%
11.5%€54.36€32.39n/a16
May ’24n/a
€43.18
0%
9.0%€53.23€35.11€27.6317
Apr ’24n/a
€43.26
0%
8.7%€53.10€35.02n/a17
Mar ’24n/a
€43.62
0%
7.3%€53.21€39.62n/a18
Feb ’24n/a
€44.78
0%
7.7%€52.95€39.43n/a18
Jan ’24n/a
€46.87
0%
8.4%€55.81€40.69n/a18
Dec ’23n/a
€46.97
0%
8.4%€55.83€40.71n/a18

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 05:34
End of Day Share Price 2024/12/19 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

British American Tobacco p.l.c. is covered by 47 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pierre-Yves GauthierAlphaValue
David ColemanArgus Research Company
Michael SteereAvior Capital Markets